Adenovirus p53 purging for human breast cancer stem cell products

Acta Haematologica

Volumn 101, Issue 2, 1999, Pages 97-105

  Hirai, Manabu ^a   Kelsey, Linda S ^a   Maneval, Daniel C ^b   Vaillancourt, Mei ^b   Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenovirus; Breast cancer; Clonogenic growth; p53; Purging

Indexed keywords

GALACTOSIDASE; PROTEIN P53;

ADENOVIRUS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLONOGENESIS; CONFERENCE PAPER; CONTAMINATION; HUMAN; HUMAN CELL; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TEMPERATURE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0032908718     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040931     Document Type: Conference Paper

References (36)

1. Myers SE, Mick R, Williams SF: High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994;13:449-454.
2. Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, Manson S, Pruett J, Cobleigh MA, Wolter J, et al: Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995;1:40-46.
3. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995;13: 2483-2489.
4. Kennedy MJ: High-dose chemotherapy of breast cancer: Is the question answered. J Clin Oncol 1995;13:2477-2479.
5. To LB, Haylock DN, Simmons PJ, Juttner CA: The biology and clinical uses of blood stem cells. Blood 1997;89:2233-2258.
6. Vahdat L, Antman KH, Armitage JO, Antman KH: High Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore, Williams & Wilkins, 1995, p 802.
7. Brenner M, Rill D, Moen R: Gene marking and autologous bone marrow transplantation. Ann NY Acad Sci 1993;716:204-215.
8. Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, et al: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-3076.
9. Sharp JG: Micrometastases and transplantation. J Hematother 1996;5:519-524.
10. Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM: The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis. Am J Clin Pathol 1988;90:1-6.
11. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-1539.
12. Porro G, Menard S, Tagliabue E, Orefice S, Salvadori B, Squicciarine P, Andreola S, Rilke F, Colnaghi M: Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients. Cancer 1988;61:2407-2411.
13. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-1756.
14. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, et al: Detection and viability of tumor cells in peripheral blood stem cell collections breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-2610.
15. Chen P, Chen Y, Bookstein R, Lee W: Genetic mechanisms of tumor suppression by the human p53 gene. Science 1990;250:1576-1580.
16. Ozbun MA, Butel JS: Tumor suppressor p53 mutations and breast cancer: A critical analysis. Adv Cancer Res 1995;66:71-141.
17. Wroblewski JM, Lay LT, Van Zant G, Phillips G, Seth P, Curiel D, Meeker TC: Selective elimination (purging) of contaminating malignant cells from hematopoietic stem cell autografts using recombinant adenovirus. Cancer Gene Ther 1996;3/4:257-264.
18. Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard M, Maneval DC: Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther 1996;3/2:121-130.
19. Seth P, Brinkmann U, Schwartz GN, Katayose D, Gress R, Pastan I, Cowan K: Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging. Cancer Res 1996;56: 1346-1351.
20. Chen L, Pulsipher M, Chen D, Sieff C, Elias A, Fine HA, Kufe DW: Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources. J Clin Invest 1996;98:2539-2548.
21. Watanabe T, Kuszynski C, Ino K, Heimann DG, Shephard M, Yasui Y, Maneval DC, Talmadge JE: Gene transfer into human bone marrow hematopoietic cells mediated by adenovirus vectors. Blood 1996;87:5032-5039.
22. Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson S, Wen SF, et al: Development and characterization of recombinant adenovirus encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079-1088.
23. Sharp JG, Kessinger A, Vaughan WP, Mann S, Crouse DA, Dicke K, Masih A, Weisenberger DD: Detection and clinical significance of minimal tumor contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10(suppl 1):92-94.
24. Ross AA, Cooper BW, Lazarus HM, Peters WP, Vredenburgh JJ, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, et al: Incidence of tumor cell contamination in peripheral blood stem cell collections from breast cancer patients. Proc Am Soc Clin Oncol 1993;12:69a.
25. Sharp JG, Joshi SS, Armitage JO, Bierman P, Coccia PF, Harrington DS, Kessinger A, Crouse DA, Mann SL, Weisenburger DD: Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by a culture technique. Blood 1992;79: 1074-1080.
26. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-383.
27. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341:85-86.
28. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for b-cell lymphoma. N Engl J Med 1991;325: 1525-1533.
29. Brockstein BE, Ross AA, Moss TJ, Kahn DG, Hollingsworth K, Williams SF: Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother 1996;5: 617-624.
30. Rummel SA, Van Zant G: Future paradigm for autologous bone marrow transplantation: Tumor purging and ex vivo production of normal stem and progenitor cells. J Hematother 1994; 3:213-218.
31. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen Schaub LB, Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54: 2287-2291.
32. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P: Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1995;1:889-897.
33. Seth P, Rosenfeld M, Higginbotham J, Crystal RG: Mechanism of enhancement of DNA expression consequent to cointernalization of a replication-deficient adenovirus and unmodified plasmid DNA. J Virol 1994;68:933-940.
34. Nielsen LL, Dell J, Maxwell E, Armstrong L, Maneval DC, Catino JJ: Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997;4/2:129-138.
35. Li H, Lochmuller H, Wee Yong V, Karpati G, Nalbantoglu J: Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J Neuropathol Exp Neurol 1997;56:872-878.
36. Seth P, Katayose D, Li Z, Kim M, Wersto R, Craig C, Shanmugan N, Ohri E, Mudahar B, Rakkar AN, et al: A recombinant adenovirus expressing wild type p53 induces apoptosis in drug-resistant human breast cancer cells: A gene therapy approach for drug-resistant cancers. Cancer Gene Ther 1997;4:383-390.